etrials Collaborates with Microsoft to Offer Software Solutions That Provide Enhanced Global Reach for Conducting Clinical Trials.

Collaboration to Offer Wireless Electronic Patient Reported Outcome (ePRO) Solutions to CRO and Pharmaceutical Sponsor Companies on a Global Scale

MORRISVILLE, N.C. -- etrials[R] Worldwide, Inc. (Nasdaq: ETWC)(Nasdaq: ETWCW)(Nasdaq: ETWCU), a leading provider of eClinical software and services that optimize clinical-trial management and accelerate time-to-market, today announced it is collaborating with Microsoft Corporation to offer an electronic patient reported outcome (ePRO) software solution that is standardized globally on Microsoft Windows Mobile-enabled devices.

etrials is currently leading the clinical research industry as one of the first global ePRO solutions provider to standardize on Windows Mobile. The Company has been standardized on Microsoft platforms since 1999 and has since seen its adoption rate climb exponentially year over year. Since launching etrials eDiary solution, etrials has deployed its software on more than 20,000 Windows Mobile devices and initiated its collaboration with Microsoft to offer consistent deployment on a standard platform for all ePRO devices.

"Microsoft's collaboration with etrials Worldwide is a significant step for the clinical research industry, as the value of offering flexible ePRO tools to patients rapidly grows," said Paul Mattes, Industry Solutions Director, Microsoft's U.S. Life Sciences Group. "etrials has demonstrated its leadership through the execution of innovative and forward-thinking strategic initiatives, including its selection of the Windows Mobile platform for its ePRO software."

The level of adaptability with ePRO devices is greatly increased using the Windows Mobile platform, as sponsors increasingly select eClinical tools based on how effectively the tool can accompany the abilities, competency and lifestyle of particular patient groups. The standardization on Windows Mobile grants etrials the ability to offer worldwide pharmaceutical clients and CRO partners increased flexibility and functionality with its wireless (and wired) software that caters to the patient population's characteristics, preferences and demographics.

Compared to other operating systems that eClinical providers use, Windows Mobile software is designed to accommodate various screen dimensions including that of the tablet, PDA, smartphone and laptop, and offers a broad selection of font styles for greater visibility and ease of use. The platform also allows for multiple applications to run simultaneously, unlike other operating systems used for ePRO tools.

"This alliance with Microsoft demonstrates our technology leadership and progressive mindset, with our clients' best interests driving our strategy," said John Cline, CEO of etrials. "Our integrated technologies are designed to solve problems, and we feel that the Windows Mobile platform is the only one designed to do that."

Supporting Information:

For more information on this topic and other Windows Mobile enabled ePRO solutions, visit http://www.clinpage.com/article/a_palm_smackdown/ to review an article title, "A Palm ePRO Smackdown," recently written by Mark Uehling, Founder and Editor of ClinPage.

About etrials([R])

etrials Worldwide, Inc. (Nasdaq: ETWC)(Nasdaq: ETWCW)(Nasdaq: ETWCU) a leading provider of eClinical software and services to pharmaceutical, biotechnology, medical device, and contract research organizations offers insight into all aspects of clinical trials, maximizing return on investment and accelerating time to market. With global operations, etrials is the only top tier solutions provider to offer electronic data capture (EDC), interactive voice response (IVR), electronic patient diaries (eDiaries), and a clinical trials management system (CTMS) as part of an integrated software as a service (SaaS) platform or as individual solutions to optimize clinical trials. As an experienced leader, etrials has facilitated over 900 trials involving more than 400,000 patients in 60 countries; and has participated in 33 studies used for new drug applications. Having partnered with over 100 clients, including 16 of the top 20 global pharmaceutical companies and top CROs, etrials is leading the way towards Adaptive Trials and integration between eClinical and electronic health records. To learn more visit us at www.etrials.com.

etrials is registered trademark in the United States of etrials Worldwide, Inc. Other marks belong to their respective owners and used with permission.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements regarding the expected number and size of clinical trials expected to be covered by a new contract. These statements involve risks and uncertainties. Actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to, delays in the current schedule for clinical trials by the client, utilization of our software and services by clients to a lesser degree than is currently expected and early termination of the contract, all of which are possible because our contracts do not generally have minimum volume guarantees and can be terminated without penalty by clients. More information about potential factors which could cause actual results to differ from the forward looking statements included in this announcement is included in our filings with the Securities and Exchange Commission, including the "Risk Factors" Section of the Form 8-K/A filed on March 31, 2006. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements.

etwcg